| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ARIAD PHARMACEUTICALS INC | 12,850,000 | 159,853,000 | 44.03% | ||
| 2 | BIOGEN INC | 310,000 | 87,909,000 | 24.21% | ||
| 3 | MEDICINES CO | 1,752,000 | 59,462,000 | 16.38% | ||
| 4 | INNOVIVA INC COM | 2,975,000 | 31,832,000 | 8.77% | ||
| 5 | NOVELION THERAPEUTICS INC | 1,025,000 | 8,630,000 | 2.38% | ||
| 6 | INTRA CELLULAR THERAPIES INC COM | 360,000 | 5,432,000 | 1.50% | ||
| 7 | ADVAXIS INC COM NEW | 500,000 | 3,579,000 | 0.99% | ||
| 8 | VIVUS INC | 2,573,943 | 2,960,000 | 0.82% | ||
| 9 | APRICUS BIOSCIENCES INC | 1,447,906 | 1,882,000 | 0.52% | ||
| 10 | AVEO PHARMACEUTICALS INC | 1,700,000 | 917,000 | 0.25% | ||
| 11 | ABBVIE INC | 10,000 | 626,000 | 0.17% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001140361-17-007278, filed 2017.02.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
